Protective effect of optimization of the whole blood separation process to prepare therapeutic-grade platelet lysate on cardiomyocytes from hypoxic injury

• Optimized whole blood separation process enables production of therapeutic-grade platelet lysate with high concentrations of growth factors. • Platelet lysate prepared by freeze-thawing is free from bacterial and mycoplasma contamination, ensuring safety for potential clinical use. • Low concentration (1%) platelet lysate significantly enhances cardiomyocyte proliferation and protects against hypoxic injury by upregulating antioxidant enzymes (SOD and GSH-Px). • Platelet lysate shows promise as a cost-effective and efficient supplement for cardiac tissue engineering and regenerative medicine.